The New York Times are reporting that the European drug giant Sanofi-Aventis was the mystery bidder for the biotechnology company ImClone Systems last month.
Shares of ImClone soared last week after the company announced that Carl C. Icahn, who holds a stake of nearly 14 percent in the company, had scuttled a potential takeover offer of $36 a share from a “major international pharmaceutical company” last month.
The disclosure of a would-be suitor, which ImClone did not identify, became the latest point of contention in an escalating battle between Mr. Icahn and the company.
Mr. Icahn said last week that ImClone was worth more than $36 a share “if it is run by competent people.”
More at the NYT
No comments:
Post a Comment